Is Stoke Therapeutics, Inc. (STOK) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 10.7% / 30% | 0.0% / 30% | 0.68% / 5% | ✓ HALAL |
| DJIM | 0.1% / 33% | 10.7% / 33% | 0.0% / 33% | 0.68% / 5% | ✓ HALAL |
| MSCI | 0.9% / 33% | 79.9% / 33% | 0.3% / 33% | 0.68% / 5% | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 10.7% / 33% | 0.0% / 33% | 0.68% / 5% | ✓ HALAL |
| FTSE | 0.9% / 33% | 79.9% / 33% | 0.3% / 50% | 0.68% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -4382.2% | |
| Net Margin | -3.7% | |
| Return on Equity (ROE) | -2.4% | |
| Return on Assets (ROA) | -3.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $46M |
| Free Cash Flow | $45M |
| Total Debt | $3M |
| Debt-to-Equity | 1.2 |
| Current Ratio | 5.3 |
| Total Assets | $418M |
Price & Trading
| Last Close | $33.70 |
| 50-Day MA | $32.90 |
| 200-Day MA | $25.54 |
| Avg Volume | 747K |
| Beta | 1.2 |
|
52-Week Range
$5.35
| |
About Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Purification Calculator
As a halal stock with 0.68% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Stoke Therapeutics, Inc. (STOK) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Stoke Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Stoke Therapeutics, Inc.'s debt ratio?
Stoke Therapeutics, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.9%.
Does Stoke Therapeutics, Inc. require dividend purification?
Yes, Stoke Therapeutics, Inc. has an impermissible income ratio of 0.68%, which means 0.68% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Stoke Therapeutics, Inc.'s key financial metrics?
Stoke Therapeutics, Inc. has a market capitalization of $1.9B, and revenue of $184M. The company maintains a gross margin of 100.0% and a net margin of -3.7%. Return on equity stands at -2.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.